Cyxone Past Earnings Performance
Past criteria checks 0/6
Cyxone has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 85.9% per year.
Key information
4.1%
Earnings growth rate
24.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 85.9% |
| Return on equity | -59.0% |
| Net Margin | -446.6% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Cyxone makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -23 | 24 | 0 |
| 30 Sep 23 | 6 | -18 | 25 | 0 |
| 30 Jun 23 | 6 | -23 | 30 | 0 |
| 31 Mar 23 | 8 | -32 | 37 | 0 |
| 31 Dec 22 | 6 | -42 | 46 | 0 |
| 30 Sep 22 | 0 | -54 | 52 | 0 |
| 30 Jun 22 | 0 | -54 | 52 | 0 |
| 31 Mar 22 | 0 | -53 | 51 | 0 |
| 31 Dec 21 | 0 | -45 | 43 | 0 |
| 30 Sep 21 | 0 | -43 | 41 | 0 |
| 30 Jun 21 | 0 | -45 | 43 | 0 |
| 31 Mar 21 | 0 | -47 | 46 | 0 |
| 31 Dec 20 | 0 | -49 | 47 | 0 |
| 30 Sep 20 | 0 | -46 | 44 | 0 |
| 30 Jun 20 | 0 | -46 | 44 | 0 |
| 31 Mar 20 | 0 | -39 | 37 | 0 |
| 31 Dec 19 | 0 | -35 | 33 | 0 |
| 30 Sep 19 | 0 | -47 | 45 | 0 |
| 30 Jun 19 | 0 | -39 | 37 | 0 |
| 31 Mar 19 | 0 | -36 | 34 | 0 |
| 31 Dec 18 | 0 | -32 | 31 | 0 |
| 30 Sep 18 | 0 | -14 | 8 | 0 |
| 30 Jun 18 | 0 | -11 | 5 | 0 |
| 31 Mar 18 | 0 | -10 | 4 | 0 |
| 31 Dec 17 | 0 | -9 | 2 | 0 |
| 30 Sep 17 | 0 | -7 | 6 | 0 |
| 30 Jun 17 | 0 | -7 | 4 | 0 |
| 31 Mar 17 | 0 | -5 | 2 | 0 |
| 31 Dec 16 | 0 | -4 | 1 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
Quality Earnings: 4CX is currently unprofitable.
Growing Profit Margin: 4CX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4CX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare 4CX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4CX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 4CX has a negative Return on Equity (-59.01%), as it is currently unprofitable.